The 2026 Cholesterol Guidelines: What Actually Changed, and Why It Matters for You
By John Bartemus, DC, CFMP, Functional Medicine Charlotte, PC. Published July 15, 2026.
Short answer: In March 2026, the ACC and AHA released an updated dyslipidemia guideline with three changes worth knowing. It retired a widely used risk calculator that overestimated 10-year heart attack and stroke risk by roughly 40 to 50 percent. It made lipoprotein(a) testing near-universal. And it elevated ApoB as a more accurate risk marker for metabolic patients. Together these shift the conversation from a single cholesterol number toward a more precise picture of who is actually at risk.
Every few years the major cardiology bodies update how cholesterol and cardiovascular risk should be managed. The 2026 update from the American College of Cardiology and the American Heart Association is a meaningful one, and parts of it echo what I have taught for years: total cholesterol is a crude tool, and better markers tell a truer story. Here is what changed, in plain English, and what it means for you.
The headline: a retired risk calculator that overstated your risk
For over a decade, clinicians estimated a patient’s 10-year risk of heart attack and stroke using a tool called the Pooled Cohort Equations. That number often decided whether you were told you needed a statin. The 2026 guideline replaces it with a newer equation called PREVENT, and the reason is significant: the older equations overestimated 10-year risk by roughly 40 to 50 percent.
Read that again. A risk score built into routine cardiology for years was systematically inflating risk. If you were told in the last decade that your numbers put you on the edge of needing medication, that assessment may have been based on an overestimate. This is not a reason to ignore cardiovascular risk, which is real and remains the leading cause of death. It is a reason to make sure your risk is measured accurately before major decisions are made. Precision matters in both directions.
Lipoprotein(a): measure it once, for life
The second change is one I am glad to see. The guideline gives lipoprotein(a), written Lp(a), a Class 1 recommendation, the strongest category, essentially calling for every adult to have it measured at least once.
Lp(a) is a particle that raises cardiovascular risk independently of your standard cholesterol. What makes it different is that it is largely genetic. Your level is set by inheritance and stays relatively stable throughout life, which is exactly why a single measurement is so useful. You test once, and you know. The thresholds the guideline gives are practical: a level of 125 nmol/L (or 50 mg/dL) or higher is associated with roughly a 1.4-fold increase in long-term heart attack or stroke risk, and 250 nmol/L with at least a two-fold increase.
This matters because Lp(a) explains a real subset of people who have heart attacks despite otherwise unremarkable cholesterol. If it is elevated, it does not mean you are helpless; it means your prevention plan needs to be more thorough, and that the people who share your genes may want to be tested too.
ApoB: counting the particles, not just the cargo
The third change elevates a marker called ApoB. To understand why it is more informative than LDL, a quick analogy helps. Picture your bloodstream as a highway and the artery-damaging particles as trucks. Standard LDL cholesterol estimates the total cargo those trucks are carrying. ApoB counts the actual number of trucks. Since it is the particles themselves that lodge in artery walls and drive damage, counting them directly is often the better measure of risk.
The 2026 guideline is specific about who benefits most. ApoB may be more accurate than LDL for assessing residual risk in people with cardiovascular kidney metabolic syndrome, type 2 diabetes, high triglycerides, or known cardiovascular disease who have already reached their standard cholesterol goals. In other words, it is built for the patient who looks fine on a basic panel but is not actually in the clear. That is frequently the person with underlying insulin resistance, whose particle picture is worse than their cholesterol number suggests.
The LDL goals, for reference
The guideline keeps tiered LDL cholesterol goals based on risk. As a general reference: under 100 mg/dL for borderline or intermediate risk, under 70 mg/dL for high risk, and under 55 mg/dL for those with established cardiovascular disease at very high risk. ApoB goals align with these tiers. These are targets to discuss with your clinician in the context of your full risk picture, not numbers to self-manage.
Where this fits with a root-cause approach
Statins remain the stated foundation of lipid-lowering therapy in this guideline, and for higher-risk patients that reflects real evidence. My work has never been anti-testing or anti-treatment. It has been about asking the next question: what is driving the particles in the first place?
Better markers make that question easier to answer, not harder. A high ApoB or a poor triglyceride-to-HDL ratio usually points back to the same upstream drivers I write about in my article on cholesterol and heart disease: too much sugar and refined carbohydrate, insulin resistance, chronic inflammation, and the lifestyle factors that feed them. The 2026 guideline gives you a sharper lens. Root-cause work decides what you do once you can see clearly. The two are complementary.
What to do with this
Ask your clinician to measure your lipoprotein(a) at least once. If it is elevated, make your prevention plan more thorough and consider testing close relatives.
If you have metabolic syndrome, diabetes, high triglycerides, or known heart disease, ask whether ApoB gives a more accurate read than your standard panel.
If a statin decision was made using an older risk score, it is reasonable to ask whether re-running your risk with the PREVENT equation changes the picture.
Address the upstream drivers: reduce sugar and refined carbohydrates, improve insulin sensitivity, and lower inflammation.
Do not start, stop, or change any medication on your own. Use these tools in partnership with your clinician.
The bottom line
The 2026 cholesterol guidelines move standard cardiology closer to a more precise, particle-focused, genetically informed view of risk, and they openly acknowledge that the old risk math ran high. For patients, the practical wins are simple: get your Lp(a) measured once, ask about ApoB if you are metabolically at risk, and make sure any medication decision rests on an accurate risk estimate. Then do the upstream work that determines your risk in the first place.
Frequently asked questions
What changed in the 2026 cholesterol guidelines?
Three notable changes: the old Pooled Cohort risk calculator, which overestimated 10-year risk by roughly 40 to 50 percent, was replaced with PREVENT; lipoprotein(a) testing became near-universal with a Class 1 recommendation; and ApoB was elevated as a more accurate marker for people with metabolic syndrome, diabetes, or high triglycerides.
What is lipoprotein(a) and should I be tested?
Lp(a) is a genetically determined particle that independently raises cardiovascular risk. The 2026 guideline recommends every adult measure it at least once. Because it is set by your genes, a single test can inform your risk for life. Levels of 125 nmol/L (or 50 mg/dL) or higher carry about a 1.4-fold increase in long-term risk; 250 nmol/L, at least two-fold.
Is ApoB better than LDL cholesterol?
ApoB counts the actual number of artery-damaging particles, while LDL estimates the cholesterol they carry. The 2026 guideline says ApoB may be more accurate for assessing residual risk in people with metabolic syndrome, type 2 diabetes, high triglycerides, or known cardiovascular disease, especially when a standard panel looks reassuring.
Does the 2026 guideline still recommend statins?
Yes. Statins remain the stated foundation of lipid-lowering therapy. What changed is more precise risk assessment through PREVENT, universal Lp(a) testing, and ApoB for selected patients. Any medication decision should be made with your prescribing clinician.
About the author: Dr. John Bartemus, DC, CFMP, is a functional medicine practitioner, educator, speaker, and Amazon international number one best-selling author focusing on optimizing cardiometabolic health, cholesterol, inflammation, and root-cause medicine through Functional Medicine Charlotte, PC.
This article is for educational purposes only and is not medical advice. It is not a recommendation to start, stop, or change any medication. Discuss your individual cardiovascular risk and treatment with a qualified clinician.
Sources: 2026 ACC/AHA Guideline on the Management of Dyslipidemia (Circulation and JACC); ACC/AHA press release, March 13, 2026.
Blumenthal, Roger S et al. “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology vol. 87,19 (2026): 2624-2757. doi:10.1016/j.jacc.2025.11.016
